Study Stopped
Lack of inclusion due to changed medical practice
Recruitment Maneuvers in ARDS: Effects on Respiratory Function and Inflammatory Markers.
1 other identifier
interventional
30
1 country
1
Brief Summary
Acute Respiratory Distress Syndrom is associated to lung and systemic inflammation, which could be worsened by mechanical ventilation.This included a proteasis - antiproteasis imbalance which could participate to a fibrosis process. Low tidal-volume ventilation (6 mL/kg) with low plateau pressure (\< 30 cm H2O) has been proved to decrease mortality when compared with more conventionnal high-volume (12 mL/kg) ventilation.Moreover, this lung-protective approach decrease lung annd systemic inflammation. Using recruitment maneuvers (i.e. the application during a short time of high pressures with the intention to re-open the lung, followed by an increase of PEEP-level to keep the lung open, in an attempt to decrease the alveolar shear-stress) has been proposed to improve oxygen and to reduce bio-trauma. However, the effect of such maneuvers on the inflammatory response and on the evolution of ARDS remains unknown. Therefore we have planned a randomized, monocentric, controlled trial consisting of the comparison of two approaches of mechanical ventilation in Acute Lung Injury. This trial will include 30 hemodynamically stable patients fulfilling the ALI or ARDS criteria defined by the US and European Consensus Conference. They will be randomized in two groups: standard low-volume ventilation vs. recruitment maneuvers. The main objective of our study is to compare both ventilatory strategies in termes of lung and systemic inflammation. The primary outcome measures will be the proteasis activity as measured in broncho alveolar fluid (BAL) and pro- and antiinflammatory cytokines activity as measured in the BAL and in the blood. Two samples (BAL and blood) will be obtained at a 48-72 hours interval. In the recruitment maneuver group, the first BAL will be obtained two hours before the maneuver. Secondary outcome measures will be gaz exchange, respiratory mechanics, systemic hemodynamics and visceral dysfunction scores.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2005
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2005
CompletedFirst Submitted
Initial submission to the registry
December 5, 2005
CompletedFirst Posted
Study publicly available on registry
December 7, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2006
CompletedJanuary 16, 2017
February 1, 2010
4 months
December 5, 2005
January 13, 2017
Conditions
Outcome Measures
Primary Outcomes (2)
proteasis activity as measured in broncho alveolar fluid (BAL)
pro- and antiinflammatory cytokines activity as measured in the BAL and in the blood.
Secondary Outcomes (4)
gaz exchange
respiratory mechanics
systemic hemodynamics
visceral dysfunction scores.
Interventions
Eligibility Criteria
You may qualify if:
- age over 18
- hospitalization in the ICU
- under mechanical ventilation
- Acute Lung Injury (ALI)criteria
- first week of ALI
- hemodynamic stability (mAP \> 75 mmHg since one hour)
- informed consent signed (patient or relatives)
You may not qualify if:
- pregnancy
- obesity (BMI \> 40 kg/M2)
- high probability of D-28 death
- severe burn injury
- severe hepatic cirrhosis (Child-Pugh C)
- aplasia
- HIV or CHV infection
- use of more than 0.5 mg/kg of steroïds
- immunosuppressor agents
- hemopathy
- contra indications for BAL
- contra indications for recruitment maneuvers
- baro-traumatism
- left cardiac failure
- chronic respiratory failure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital of Tours
Tours, 37044, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Gilles Rival, MD
University Hospital of Tours
- STUDY CHAIR
Pierre-Francois Dequin, MD, PhD
University Hospital of Tours
- STUDY DIRECTOR
Francis Gauthier, PhD
Inserm U-618
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 5, 2005
First Posted
December 7, 2005
Study Start
September 1, 2005
Primary Completion
January 1, 2006
Study Completion
January 1, 2006
Last Updated
January 16, 2017
Record last verified: 2010-02